All In Biotech

NDA 021014 · Novartis

Trileptal

Oxcarbazepine · Oral · Anti-epileptic Agent

Novel

Last checked: Nov 19, 2026Latest source record: Sep 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Jan 14, 2000

Approved uses

3

Original approval plus efficacy supplements

Registered trials

62

13 Phase 3, 2 recruiting

FAERS reports

31,740

24,137 serious, 2,192 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 28, 2026.

TRILEPTAL is indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures. TRILEPTAL is indicated for: Adults: Monotherapy or adjunctive therapy in the treatment of partial-onset seizures Pediatrics: - Monotherapy in the treatment of partial-onset seizures in children 4-16 years - Adjunctive therapy in the treatment of partial-onset seizures in children 2-16 years ( 1 )

Mechanism: The pharmacological activity of TRILEPTAL is primarily exerted through the 10-monohydroxy metabolite (MHD) of oxcarbazepine [ see Clinical Pharmacology (12.3) ]. The precise mechanism by which oxcarbazepine and MHD exert their anti-seizure effect is unknown; however, in vitro electrophysiological studies indicate that they produce blockade of voltage-sensitive sodium channels, resulting in stabilization of hyperexcited neural membranes, inhibition of repetitive neuronal firing, and diminution of propagation of synaptic impulses. These actions are thought to be important in the prevention of...

Therapeutic areas: Neurology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • TRILEPTAL · OXCARBAZEPINE 300MG · TABLET, ORAL · Prescription · TE AB
  • TRILEPTAL · OXCARBAZEPINE 600MG · TABLET, ORAL · Prescription · TE AB
  • TRILEPTAL · OXCARBAZEPINE 150MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Oxcarbazepine" as an intervention, any sponsor and status, largest first.

All 62 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective2,931
  • seizure2,829
  • off label use1,726
  • dizziness1,533
  • fatigue1,465
  • convulsion1,455
  • nausea1,317
  • headache1,301
  • somnolence1,251
  • fall1,208
  • hyponatraemia1,183
  • vomiting1,131

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004631
2005749
2006782
2007779
2008722
20091,057
20101,058
20111,110
20121,389
20131,153
20141,247
20151,809
20161,930
20171,761
20181,893
20191,919
20201,795
20211,803
20221,644
20231,758
20241,747
20251,711
20261,290

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Trileptal (Oxcarbazepine)

2024 spending

$19.4M

Beneficiaries

1,548

10,640 claims

Per beneficiary

$12,548

$11.79 per unit

View as table
YearSpending
2020$21,734,725
2021$20,129,436
2022$20,037,373
2023$20,960,477
2024$19,424,100

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 339 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.